Cargando…

Pharmacological Intervention to Modulate HDL: What Do We Target?

The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woudberg, Nicholas J., Pedretti, Sarah, Lecour, Sandrine, Schulz, Rainer, Vuilleumier, Nicolas, James, Richard W., Frias, Miguel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786575/ https://www.ncbi.nlm.nih.gov/pubmed/29403378 http://dx.doi.org/10.3389/fphar.2017.00989

Ejemplares similares

HDL Subclass Distribution Shifts with Increasing Central Adiposity
por: Woudberg, Nicholas J., et al.
Publicado: (2019)

Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution
por: Woudberg, Nicholas J., et al.
Publicado: (2016)

Exercise intervention alters HDL subclass distribution and function in obese women
por: Woudberg, Nicholas J, et al.
Publicado: (2018)

Improving Reconstituted HDL Composition for Efficient Post-Ischemic Reduction of Ischemia Reperfusion Injury
por: Brulhart-Meynet, Marie-Claude, et al.
Publicado: (2015)

HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3
por: Pedretti, Sarah, et al.
Publicado: (2019)

Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
por: Abrahams, Carmelita, et al.
Publicado: (2022)

High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway
por: Frias, Miguel A., et al.
Publicado: (2012)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
por: Lacroix, Clémence, et al.
Publicado: (2022)

Contextualising the Perceptions of Pharmacists Practicing Clinical Pharmacy in South Africa—Do We Practice what We Preach?
por: Bronkhorst, Elmien, et al.
Publicado: (2021)

Antioxidant properties of HDL
por: Soran, Handrean, et al.
Publicado: (2015)

Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain?
por: Matthews, Philippa C., et al.
Publicado: (2022)

HDL in sepsis – risk factor and therapeutic approach
por: Morin, Emily E., et al.
Publicado: (2015)

Protective Effects of HDL Against Ischemia/Reperfusion Injury
por: Gomaraschi, Monica, et al.
Publicado: (2016)

HDL as a drug and nucleic acid delivery vehicle
por: Lacko, Andras G., et al.
Publicado: (2015)

HDL particle number and size as predictors of cardiovascular disease
por: Kontush, Anatol
Publicado: (2015)

HDL and glucose metabolism: current evidence and therapeutic potential
por: Siebel, Andrew L., et al.
Publicado: (2015)

Phytotherapy for Cachexia: Where Do We Stand?
por: Kuchta, Kenny, et al.
Publicado: (2020)

Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them
por: Amaral, Leonard, et al.
Publicado: (2014)

Pharmacological Modulation of BET Family in Sepsis
por: Wang, Nian, et al.
Publicado: (2021)

Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis
por: Choi, Hong Y., et al.
Publicado: (2021)

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)

Connexin 43 in Mitochondria: What Do We Really Know About Its Function?
por: Boengler, Kerstin, et al.
Publicado: (2022)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications
por: Levkau, Bodo
Publicado: (2015)

Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy
por: Raut, Sangram, et al.
Publicado: (2018)

Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach
por: Gadkar, Kapil, et al.
Publicado: (2016)

Cardiovascular imaging: what have we learned from animal models?
por: Santos, Arnoldo, et al.
Publicado: (2015)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Particle Physics Outreach: What we are doing and what we could be doing
por: Goldfarb, Steven
Publicado: (2018)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Keeping the Journal in the Second Quarter: What Are We Doing and What Will We Do?
por: Altay, Servet
Publicado: (2023)

The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells—a Potential Target for Pharmacological Intervention in Cardiovascular Diseases
por: Vukićević, Tanja, et al.
Publicado: (2016)

Lipid Membranes as Key Targets for the Pharmacological Actions of Ginsenosides
por: Verstraeten, Sandrine L., et al.
Publicado: (2020)

Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis
por: Li, Le, et al.
Publicado: (2023)

Pharmacological Interventions for Bacterial Prostatitis
por: Xiong, Situ, et al.
Publicado: (2020)

The risk of viral transmission in feed: What do we know, what do we do?
por: Dee, Scott A., et al.
Publicado: (2020)

Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor
por: Pardon, Marie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sr2gj0ob6ub8inkqj1s2vqg3o8